Korean Biotech Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:00
Sep 18
Sep 18
Korean biotech lacks supply; avoid Alteogen.
Korean biotech sentiment is poor because the large speculative funds that used to drive the sector have been hurt by earlier losses. Alteogen's fundamentals are not bad, but supply is not attaching; if the 250,000 won support breaks, it could struggle further until institutions or foreigners return.
MED
08:09
Sep 18
Sep 18
Avoid Korean biotech on weak supply
Korean biotech sentiment is weak, supply has dried up after extended losses, and several regulatory and sentiment issues are weighing on the group. Until institutions or foreigners get a strong catalyst, the sector is likely to struggle.
MED
02:19
Sep 16
Sep 16
Korean biotech cannot beat high rates
Domestic Korean biotech is not in an environment that can beat high rates. Even cash-generating platform names such as Celltrion, Alteogen, and Samsung Biologics are not moving much, and only companies with individual conference or pipeline catalysts may rebound intermittently. Broad Korean biotech exposure is unattractive while yields stay near 5%.
MED
13:30
Sep 09
Sep 09
Add KOSDAQ biotech; rebound must participate.
Shin argues that if KOSDAQ is going to rise, biotech must participate, so even though he had reduced his biotech weighting, he thought from today it was time to start adding back. Biotech is one of the core KOSDAQ growth sectors that led the rebound and can continue in rotation.
MED
12:30
Sep 04
Sep 04
Korean biotech bottoming on rate catalysts.
Korean biotech sentiment has already deteriorated about as much as it can with rates near a peak, so the sector has limited room for further sentiment damage. Licensing-out news or lower and more stable rates could quickly trigger moves in many biotech names.
MED
02:03
Sep 01
Sep 01
Four sectors where earnings and narrative align
Prefers a concentrated four-sector portfolio of semiconductors, electric electronics, power equipment, and biotech because those are the sectors where earnings and narrative, the two engines that move stock prices, currently align. His disclosed allocation was 31% semiconductors, 17% power equipment, 13% electric electronics, 15% biotech, and 20% cash.
HIGH
07:33
Aug 25
Aug 25
Balance AI and non-AI Korean sectors.
Investors should not chase only Samsung Electronics and SK Hynix in AI; balance AI exposure such as Samsung Electronics, SK Hynix, semiconductor materials/parts/equipment, and power equipment against non-AI sectors like cosmetics, biotech, and secondary batteries, while keeping 20-40% cash to deploy on sharp dips.
MED
04:31
Aug 24
Aug 24
KOSDAQ growth stocks are unfairly lagging US peers.
While US growth stocks like ARK Invest and biotech ETFs are hitting new highs despite rate concerns, KOSDAQ growth and biotech stocks are unfairly suppressed by local supply-demand dynamics, presenting a potential catch-up opportunity.
MED
08:00
Aug 23
Aug 23
Korean cosmetics, biotech, shipbuilding are growing.
Beyond semiconductors, Korean export data shows cosmetics and biotech have been steadily improving since last year, and shipbuilding orders have recently been good; they are too small to fully replace semiconductors if semis rest, but they are real secondary candidates.
MED
08:10
Aug 21
Aug 21
Avoid biotechs rallying purely on Moderna sympathy.
Korean biotech stocks that rallied purely in sympathy with Moderna's recent surge, without any fundamental business connection or hard data of their own, are vulnerable to sharp corrections. Moderna's own stock experienced a 20% pullback after its massive run, and Korean peers lacking solid catalysts will likely face similar profit-taking.
MED
03:16
Aug 20
Aug 20
Buy Korean biotech targeting US tech exports.
Korean biotech stocks are attractive now, specifically those expected to license out technology to US Big Pharma in the obesity and oncology sectors. While the sector lacks broad momentum, individual companies with tangible export achievements will see strong investor sentiment improvement.
MED
23:00
Aug 19
Aug 19
Buy biotech firms with tech export potential.
Rather than buying the broad biotech sector dominated by large caps, investors should pick individual Korean biotech companies with strong potential to export technology to US Big Pharma, particularly in the obesity and oncology fields, and hold them for expected second-half results.
MED
11:03
Aug 19
Aug 19
Buy biotech in summer for winter catalysts.
Korean biotech stocks exhibit strong seasonality: buy in summer and sell in winter. Major catalysts and clinical results from global conferences typically emerge from September through winter, making the sector attractive to accumulate now.
MED
08:46
Aug 19
Aug 19
Buy biotech in summer for winter catalysts.
Korean biotech stocks exhibit strong seasonality. Investors should buy in the summer and sell in the winter, as major clinical catalysts and licensing events typically occur from September through early next year.
HIGH
04:00
Aug 13
Aug 13
KOSDAQ bio/robotics rotation likely now.
With rate-hike concerns easing and no earnings announcements near term, the non-earnings/macro-focused period favors KOSDAQ small/mid-cap strategies, especially biotech and robotics. KOSDAQ has already risen 38% from the bottom, but holding its trend without breaking down is enough for now.
MED
03:16
Aug 11
Aug 11
Korean biotech will follow US biotech highs.
US biotech stocks are hitting new historical highs, and Korean biotech stocks are likely to follow this upward trend with a time lag.
MED
00:31
Jun 30
Jun 30
Rotate from semis to biotech, cosmetics, entertainment
Second half of the year will see a broader market rally beyond semiconductors. Allocation should shift from an overweight in semiconductors (70% of equity bucket) to a more balanced 50/50 split, adding exposure to Korean biotech, cosmetics, and entertainment sectors. The rotation is driven by semiconductor rebalancing flows, government mega projects that highlight power and infrastructure, and physical AI trends that benefit robotics.
HIGH
08:27
Jun 24
Jun 24
Avoid new Korean biotech positions.
Korean biotech's rally today is not driven by fundamentals but merely a catch-up to the US biotech index which hit all-time highs. Korean biotech is structurally cyclical and sensitive to interest rates, unlike defensive US biotech. The sector lacks sustainable earnings momentum. New buying is risky; existing holders should use the bounce to reduce positions.
MED
11:00
May 20
May 20
Avoid Korean biotech for now.
The Korean biotech sector currently lacks new buying interest and has lost its appeal. Despite claims of no issues, stocks continue to fall with low volume, indicating no catalyst for a rebound. Avoid until fresh money flows in.
MED
11:00
May 18
May 18
Avoid Korean biotech sector.
The biotech sector lacks fundamental support and positive sentiment; even good news leads to profit-taking. The bottom is not confirmed, so investors should avoid trying to catch the bottom.
MED
03:00
May 13
May 13
Korean biotech sector rotation play
Korean biotech stocks are poised to rally after the Q1 earnings season ends, as money rotates from semiconductors into 'dream stocks' like biotech and robotics for May-June. Alteogen and LigaChem are examples that have already moved.
LOW
02:00
May 01
May 01
Rate reversal lifts KOSDAQ biotech
Consensus expects inflation and rate hikes, but if rates instead face downward pressure, the most suppressed assets such as Korean biotech and KOSDAQ should spring. A barbell of SK hynix plus KOSDAQ index remains a useful portfolio structure.
MED
11:12
Apr 30
Apr 30
Rebalance from laggards into leaders.
Leading sectors such as semiconductors, power infrastructure, and energy should not be sold. Non-leading names can be traded, and laggards like Naver, Kakao, and biotech can be swapped into leaders.
MED
01:09
Apr 30
Apr 30
Korean biotech set for medium-term recovery.
The Korean biotech sector has underperformed because technology-transfer deals have declined and biotechs have little earnings; its correlation with US biotech has broken, but she expects recovery over the medium to long term. Investors should focus on companies that consistently deliver results and keep development timelines, and she expects new quality IPOs to lead KOSDAQ biotech. She cautions not to expect big near-term May-June returns but sees larger multi-year upside than other sectors.
HIGH
06:00
Apr 28
Apr 28
Korean biotech hit by ETF selling
ABL Bio's clinical announcement triggered a broad selloff in Korean biotech. Many biotech stocks are linked to ETF flows, so the negative event led to correlated ETF-related selling across pharmaceuticals and biotech, making the group unattractive in the near term.
HIGH
10:09
Apr 24
Apr 24
Korean bio needs trust-restoring licensing deals.
Korean biotech lost investor trust after disappointing results from Alteogen and ABL Bio and the Sam Chun Dang issue, but if large licensing deals or other trust-restoring events occur, earnings estimates could rise again.
MED
01:05
Apr 24
Apr 24
Growth fund supports KOSDAQ capital-intensive sectors
The Korean government's National Growth Fund is being designed to channel public and private capital into future growth mega-projects, with tax benefits and some historical downside support. If implemented, it could reduce financing pressure and dilution risk for capital-intensive KOSDAQ growth sectors such as biotech, secondary batteries, and robotics, making where the money flows a useful guide for diversifying portfolios.
HIGH
03:45
Apr 23
Apr 23
Korean biotech is oversold, watch catalyst.
Korean biotech is underowned and oversold; KOSDAQ needs biotech to rise, and positive events could revive supply into large-cap biotech names.
MED
01:16
Apr 23
Apr 23
Neglected Korean biotech offers reversal opportunity.
The speaker likes Korean biotech and KOSDAQ bio because the sector has been neglected while other sectors rallied, and large-cap bio disappointments have already hurt sentiment. He sees potential for fund flows if a large-cap bio event or licensing deal appears; KOSDAQ needs bio leadership to level up, and Korean biotech is globally competitive.
MED
00:49
Apr 23
Apr 23
Korean biotech pullback looks mostly finished.
Jang says the biotech pullback caused by Sam Chun Dang Pharm's disappointing data release appears to be mostly done. Alteogen, ABL Bio, HLB and other biotech names are rebounding, so the sector's worries are easing and it is worth watching with positive expectations.
MED
About Korean Biotech Investor Commentary
Across the available history and selected sources, Buzzberg tracks Korean Biotech across 4 sources: 32 bullish vs 0 bearish calls from 26 authors. Historical directional balance: 62% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 52 total trade ideas tracked. Past 7 days, before deduplication: 3 other directions. Latest voices: Lee Kwon-hee, Park Ji-hoon, Shin Hyeok-seung.